Erbitux OK for Colorectal Cancer Patients with Genetic Marker

from USA Today

A new study shows which colorectal cancer patients may benefit from a drug - and which would be better off without it.

The drug Erbitux doesn't work in patients whose tumor has a certain genetic mutation, according to a study of nearly 600 patients, presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago.

About 36 percent of patients in the study have the mutation, in a gene called KRAS, says co-author Eric Van Cutsem, of University Hospital Gasthuisberg in Belgium. All of the patients in the study had colorectal cancer that had spread to other organs.

Science in the Media

Newspapers:

Magazines and Web Sites:

The Science-Media Intersection:

Science Blogs

Sign Up

... for Sigma Xi SmartBrief, a free daily summary of the latest news in scientific research, delivered straight to your in-box. Each story is summarized concisely and linked directly to the original source for further reading.

Click here to subscribe.

Subscribe to Our Content!

Visit our RSS Feeds page to choose among 13 customized feeds, or create a free My AmSci account to request an email notice whenever a specified author, department or discipline appears online.

EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Diesel Exhausts Do Cause Cancer, Says WHO

Science in the News Weekly: T-DM1 Treats Breast Cancer With Fewer Side Effects

Science In The News Daily: CT Scans on Children 'Could Triple Brain Cancer Risk'